November 2024 – Recently, the FDA approved Optune Lua, a groundbreaking device for the treatment of non-small cell lung cancer. The device has initially been used for treatment of glioblastoma and mesothelioma, where electrodes are placed on the skin in order to disrupt separation of chromosomes in cellular division. Developed by Novocure, a global oncology company focused on cancer treatment, Optune Lua has now been adapted to function as a vest for treating non-small cell lung cancer.
Dr. Oleg Gligich, a board-certified oncologist at the Division of Hematology/Oncology at Mount Sinai Medical Center, notes, “During the clinical trial design, not all patients received immunotherapy beforehand, which would have been the current standard of care and would have yielded an overall survival benefit. Although the study’s design was somewhat unconventional, it has received FDA approval. Unfortunately, options in second line metastatic, stage IV lung cancer are limited, with no new developments in over eight years. Optune Lua gives a refreshing novel approach to treatment with survival benefit while minimizing toxicity.”
At Mount Sinai, oncologists have been using Optune Lua with patients suffering from mesothelioma and are now preparing to start treatments for those with non-small cell lung cancer.
Learn more about our award-winning Comprehensive Cancer Center here: https://www.msmc.com/cancer
